Psyched Wellness Announces July 19th, 2022 As the Official Date To Commence Pre-Orders for Calm

The announcement comes on the company’s second anniversary, marking its growth and success

Toronto, Ontario–(Newsfile Corp. – July 13, 2022) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is celebrating its second anniversary and is thrilled to share that the previously announced pilot run of its Amanita Muscaria derived product, Calm is nearly complete and the company is ready to move forward with pre-orders. Starting July 19th, 2022, the company will begin accepting pre-orders, with products anticipated to reach consumers in the United States in the Fall of 2022.

Cannot view this image? Visit: http://www.healthtechnologynet.com/wp-content/uploads/2022/07/130760_3b19f99a14882942_002.jpg

Calm is the company’s flagship product

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6579/130760_3b19f99a14882942_002full.jpg.

Calm is the company’s flagship product, and is the first legal Amanita Muscaria mushroom extract approved for sale in the USA. It does not require a prescription, leaving the retail landscape open to many possibilities for distribution and listing potential.

“With today being Psyched Wellness’ 2nd anniversary as a company, we felt it was perfect timing to set a date for consumers in the United States to be able to pre-order Calm,” says Jeffrey Stevens, CEO of the company. “It has been a long journey to get to this point, and I would like to take this opportunity to thank my co-founder, David Shisel, our team, KGK Science and Vantage Hemp for all of their hard work and commitment to get us to where we are today. The most exciting part for me is that we have just scratched the surface with respect to potential uses and delivery forms for AME-1. Stay tuned for more to come from Psyched.”

Visit www.psyched-wellness.com for more information on how to order.

For further information, please contact:

Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: [email protected]

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

About Psyched Wellness Ltd.:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Cautionary Statement Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130760

error: Content is protected !!